Tigecycline: The answer to beta-lactam and fluoroquinolone resistance?

Journal of Infection

Volumn 53, Issue 5, 2006, Pages 293-300

  Fraise, Adam P ^a  

^a SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Beta lactam resistance; Fluoroquinolone resistance; Review; Tigecycline

Indexed keywords

AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLAVULANIC ACID; ERTAPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; SULTAMICILLIN; TAZOBACTAM; TIGECYCLINE; TIMENTIN; UNINDEXED DRUG;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; ENTEROCOCCUS; HUMAN; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NAUSEA; NEPHROTOXICITY; REVIEW; SEIZURE; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; THERAPY DELAY; VOMITING;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CLINICAL TRIALS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 33749541741     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2006.05.014     Document Type: Review

References (64)

1. Chow J.W., Fine M.J., Shlaes D.M., Quinn J.P., Hooper D.C., Johnson M.P., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Int Med 115 (1991) 585-590
2. Homberg S., Solomon S., and Blake P. Health and economic impacts of antimicrobial resistance. Rev infect Dis 9 (1987) 1065-1078
3. Phelps C. Bug/drug resistance. Sometimes less is more. Med Care 27 (1989) 194-203
4. Mandell G., and Perti W. Antimicrobial agents: penicillins, cephalosporins, and other b-lactam antibiotics. In: Hardman J., et al. (Ed). Goodman & Gilman's The Pharmacologic Basis of Therapeutics (1996), McGraw-Hill, New York 1073-1101
5. Gootz T.D. Global dissemination of beta-lactamases mediating resistance to cephalosporins and carbapenems. Expert Rev Anti Infect Ther 2 2 (2004) 317-327
6. Szabo D., Bonomo R.A., Silveira F., Pasculle A.W., Baxter C., Linden P.K., et al. SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae. J Clin Microbiol 43 10 (2005) 5058-5064
7. Sanders C.C., and Sanders Jr. W.E. Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases. Antimicrob Agents Chemother 15 6 (1979) 792-797
8. Sanders C., and Sanders W.J. Emergence of resistance during therapy with the newer ß-lactam antibiotics: role of inducible ß-lactamases and implications for the future. Rev Infect Dis 5 (1983) 639-648
9. Sanders C., and Sanders W. ß-lactam resistance in Gram-negative bacteria global trends and clinical impact. Clin Infect Dis 15 (1992) 824-839
10. Johnson M., and Ramphal R. ß-lactam resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 162 (1990) 981-983
11. Fussle R., Biscoping J., and Behr R. Development of resistance by Enterobacter cloacae during therapy of pulmonary infections in intensive care patients. Clin Invest 72 (1994) 1015-1019
12. Burwen D., Banerjee S., and Gaynes R. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 170 (1994) 1622-1625
13. Quinn J. Clinical problems posed by multiresistant non-fermenting gram-negative pathogens. Clin Infect Dis 27 (1998) S117-S124
14. Ambrose P., Richerson M., and Bui K. Cost-effectiveness analysis of cefepime versus ceftazidime in ICU patients with hospital-acquired pneumonia. Clin Infect Dis 27 (1998) 1046
15. Paterson D. Beta-lactamase inhibitors and new beta-lactamases. Curr Treat Options Infect Dis 1 (1999) 85-87
16. Ito H., Yoshida H., Bogaki-Shonai M., Niga T., Hattori H., Nakamura S., et al. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother 38 9 (1994) 2014-2023
17. Heisig P., and Tschorny R. Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother 38 6 (1994) 1284-1291
18. Paterson D.L. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 6 9 (2000) 460-463
19. Poirel L., Van De Loo M., Mammeri H., and Nordmann P. Association of plasmid-mediated quinolone resistance with extended-spectrum beta-lactamase VEB-1. Antimicrob Agents Chemother 49 7 (2005) 3091-3094
20. Mazuski J., Sawyer R., and Nathens A.e.a. The surgical infection society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect 3 (2002) 161-173
21. Solomkin J., Mazuski J., and Baron E.e.a. Guidelines for the selection of anti-infective agent for complicated intra-abdominal infections. Clin Inf Dis 37 (2003) 997-1005
22. Eng R.H., Munsif A.N., Yangco B.G., Smith S.M., Chmel H., et al. Seizure propensity with imipenem. Arch Intern Med 149 8 (1989) 1881-1883
23. Saxon A., Adelman D.C., Patel A., Hajdu R., Calandra G.B., et al. Imipenem cross-reactivity with penicillin in humans. J Allergy Clin Immunol 82 2 (1988) 213-217
24. Prescott Jr. W.A., DePestel D.D., Ellis J.J., Regal R.E., et al. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clin Infect Dis 38 8 (2004) 1102-1107
25. Elston D.M. Optimal antibacterial treatment of uncomplicated skin and skin structure infections: applying a novel treatment algorithm. J Drugs Dermatol 4 Suppl. 6 (2005) s15-s19
26. Eron L.J., Lipsky B.A., Low D.E., Nathwani D., Tice A.D., Volturo G.A., et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 52 Suppl. 1 (2003) i3-i17
27. Paul M., Benuri-Silbiger I., Soares-Weiser K., Leibovici L., et al. Beta-Lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328 7441 (2004) 668
28. Sanders W.J., Tenney J., and Kessler R. Efficacy of cefepime in the treatment of infections due to multiply resistant enterobacter species. Clin Infect Dis 23 (1996) 454-461
29. Thomas C., et al. Clostridium difficile - associated diarrhea: epidemiological data from Western Australia associated with a modified antibiotic policy. Clin Infect Dis 35 12 (2002) 1457-1462
30. Chow A., Wong J., and Bartlett K. Synergistic interactions of ciprofloxacin and extended-spectrum ß-lactams or amino-glycosides against multiply drug-resistant Pseudomonas maltophilia. Antimicrob Agents Chemother 32 (1988) 782-784
31. Cometta A., Baumgartner J., and Lew D. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in non-neutropenic patients. Antimicrob Agents Chemother 38 (1994) 1309-1313
32. Eliopoulos G., and Eliopoulos C. Ciprofloxacin in combination with other antimicrobials. Am J Med 87 Suppl. 5A (1989) 17s-22s
33. Neu H. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents. Drugs 45 Suppl. 3 (1993) 54-58
34. Stratton C., Franke J., and Weeks L. Comparison of the bactericidal activity of ciprofloxacin alone and in combination with selected antipseudomonal beta-lactam agents against clinical isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 11 (1989) 41-45
35. Wallace Jr. R.J., Brown-Elliot B.A., Crist C.J., Wallace R.J., et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of non-tuberculous mycobacteria. Antimicrob Agents Chemother 46 10 (2002) 3164-3167
36. Roblin P.M., and Hammerschlag M.R. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrobial Agents 16 1 (2000) 61-63
37. Kenny G.E., and Cartwright F.D. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 45 9 (2001) 2604-2608
38. Rhomberg P.R., and Jones R.N. In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diag Microbiol Infect Dis 42 2 (2002) 145-147
39. Edlund C., and Nord C.E. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 6 3 (2000) 159-163
40. Petersen P.J., Bradford P.A., Weiss W.J., Murphy T.M., Sum P.E., Projan S.J., et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 46 8 (2002) 2595-2601
41. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., Testa R.T., et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43 4 (1999) 738-744
42. Boucher H.W., Wennersten C.B., and Eliopoulos G.M. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 44 8 (2000) 2225-2229
43. Zhanel G.G., Palatnick L., Nichol K.A., Low D.E., Hoban D.J., et al. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 47 6 (2003) 1875-1881
44. Hoellman D.B., Pankuch G.A., Jacobs M.R., Appelbaum P.C., et al. Antipneumococcal activity of GAR 936, a new glycylcycline, compared to those of nine other agents against penicillin susceptible and resistant pneumococci. Antimicrob Agents Chemother 44 4 (2000) 1085-1088
45. Gales A.C., and Jones R.N. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 36 1 (2000) 19-36
46. Cercenado E.C.S.G.J.A.B.E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 52 1 (2003) 138-139
47. Murphy T.M., Deitz J.M., Petersen P.J., Mikels S.M., Weiss W.J., et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 44 11 (2000) 3022-3027
48. van Ogtrop M.L., Andes D., Stamstad T.J., Conklin B., Weiss W.J., Craig W.A., et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 44 4 (2000) 943-949
49. Projan S.J. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 20 9 Pt 2 (2000) 219S-223S discussion 224S-228S
50. Mercier R.-C., Kennedy C., and Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 22 12 (2002) 1517-1523
51. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 17 Suppl. 1 (2005) 12-22
52. Wilcox M. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections. J Chemother 17 Suppl. 1 (2005) 23-29
53. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E., et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 Suppl. 5 (2005) S341-S353
54. Sacchidanand S., Penn R.L., Embil J.M., Campos M.E., Curcio D., Ellis-Grosse E., et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 9 5 (2005) 251-261
55. Breedt J., Teras J., Gardovskis J., Maritz F.J., Vaasna T., Ross D.P., et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 49 11 (2005) 4658-4666
56. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M.., Loh E., et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41 Suppl. 5 (2005) S354-S367
57. Fomin P., Bouran M., Gradauskas A., Barauskas G., Datsenko A., Dartois N., et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 3 1 (2005) 35-47
58. Oliva M.E., Rekha A., Yellin A., Pasternak J., Campos M., Rose G.M., et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 5 (2005) 88
59. Milatovic D., Schmitz F.-J., Verhoef J., Fluit A.C., et al. Activities of the glycylcycline tigecycline (GAR-936) against 1924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 47 1 (2003) 400-404
60. Cercenado E., Cercenado S., Gomez J.A., Bouza E., et al. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 52 1 (2003) 138-139
61. Zhanel G.G., Palatnick L., Nichol K.A., Bellyou T., Low D.E., Hoban D.J., et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 47 6 (2003) 1867-1874
62. Betriu C., Rodriguez-Avial I., Sanchez B.A., Gomez M., Alvarez J., Picazo J.J., and Spanish Group of Tigecycline. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 46 3 (2002) 892-895
63. Postier G., Green S.L., Klein S.R., Ellis-Grosse E.J., and Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 26 5 (2004) 704-714
64. Murray J., Wilson S., Klein S., Yellin A., Loh E., et al. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients. A phase 2 clinical trial. Abstr 43rd Intersci Conf Antimicrob Agents Chemother 43 (2003) 416